Clinical aspects of platelet inhibitors and thrombus formation
about
Platelet function and ageingDo the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsPKCalpha regulates platelet granule secretion and thrombus formation in miceState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Ferric chloride-induced murine carotid arterial injury: A model of redox pathology.Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary interventionPPBP and DEFA1/DEFA3 genes in hyperlipidaemia as feasible synergistic inflammatory biomarkers for coronary heart disease.Triggers, targets and treatments for thrombosis.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry.N-substituted indole carbohydrazide derivatives: synthesis and evaluation of their antiplatelet aggregation activity.Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.An agent-based model of the response to angioplasty and bare-metal stent deployment in an atherosclerotic blood vessel.Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits.Future innovations in anti-platelet therapies.Targeting platelets for prevention and treatment of cardiovascular disease.Humanizing mouse thrombi.Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis.Platelet receptors and signaling in the dynamics of thrombus formation.Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.Current concepts about inhibition of platelet aggregation.Aspirin and Diabetes Mellitus: revisiting an old player.Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?Appropriate secondary prevention of acute atherothrombotic events and strategies to improve guideline adherence.PAR-1 inhibitor antiplatelet agents: performance below par?Platelet interactions as therapeutic targets for prevention of atherothrombosis.New antithrombotic drugs.Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Novel factor Xa inhibitors: a patent review.Mechanisms of hemolysis-associated platelet activation.Platelet thrombin receptor antagonism and atherothrombosisProtein kinase Calpha: disease regulator and therapeutic target.Emerging drugs for acute myocardial infarction.Mechanism of action and clinical development of platelet thrombin receptor antagonists.Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention
P2860
Q26749231-F0A18AA2-9267-451C-BA0C-C56C600EF3EDQ26852616-758E15CC-737F-43AE-90CF-9F9CE6DFF810Q26861200-362CD1E0-4B5A-437D-9B94-C9F66ED43CF1Q28505136-D4EF2E68-5A2C-469F-9B7C-38D3E711FCC2Q30373414-54D503F6-3187-47A9-BCB3-A051BAE5B630Q30585424-58F5F145-BB42-4BC1-96F4-C9ECFB623EE9Q33426570-6F26E71C-C74D-47F9-AE33-50BF67EDF160Q33576883-FCBAE142-CE6F-4B1A-9F50-E6A367E77C47Q33765444-6A314E46-3977-4212-B984-412A1683EF40Q33863833-445C1D34-DF14-4C33-B0D3-A160C5E8E523Q33881728-D9D39C98-69B8-4964-BD07-063776BD2EB0Q34233715-82795D3C-8914-4863-A06C-7C6BF27DD86BQ34255442-7F015A5E-A6F6-46A3-9F1A-E503F5D9E0EFQ34771381-92AEAFAC-45A4-4B0B-8B29-A739D444151CQ35147533-742437DE-A449-44D0-B1E7-C7F1CAD11DA1Q35797491-256F3487-DF4A-4683-94EF-20AFA1EC15B6Q36210649-11A9DBE3-285F-4844-836E-DAFB41DB56E7Q36753593-86A3F881-B706-4479-BAC8-DDE98287C1DCQ37004721-2E750C7D-D538-4C63-838B-C8950803A6B0Q37053547-72C00A96-9AEC-408D-A665-0DE2E4D5C78FQ37127450-F9C53F3B-F5A4-4EB0-8D24-9817290E17CDQ37175605-C46AE695-9A97-416F-962B-AA4861FBCF83Q37203951-08730C89-E593-426C-9C30-05A08755D599Q37231987-5D2C1353-5E2B-4B2D-9AB3-F30B87B48856Q37326634-F957A250-AD2D-4A8D-86AF-09C48840246FQ37362710-C7212561-2D19-4FD2-8D4D-80980CD2E4CFQ37362773-D3E6CA02-D9CD-44B7-BF2E-58EF0DC71624Q37380499-19FBB848-461F-4FDA-993D-9B835C9F7D5DQ37387238-5E84D935-FAE5-4058-9396-D0106255655CQ37486621-C0B4DCDF-DDC2-442E-BB25-4043D2909A0BQ37530424-A4C5CE27-1981-45D9-9B39-DC5B4A4489F3Q37532491-2C570D79-30F3-4F25-ACFE-D670D04718D6Q37550156-38156038-B939-4045-BC11-0269D8BB195CQ37594779-DFFAAF0C-B1FC-4C7C-97F8-45AFD6C80EDDQ37626438-CAB43BBC-3641-4785-947F-BFEE2BD89517Q37641556-FB27BE57-D1A0-41F4-8CF6-B74DC3BAA5EFQ37647208-CA6D9E31-0ED2-4DD6-BDF5-F0C388A64DECQ37670190-6CEC6B46-777D-46DF-A676-FB03C7BD5B79Q37776518-D6B08F00-5256-4996-9E54-7BB9186D613DQ37782412-CF75C4AF-25BE-4706-90D9-711D3798EA35
P2860
Clinical aspects of platelet inhibitors and thrombus formation
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical aspects of platelet inhibitors and thrombus formation
@ast
Clinical aspects of platelet inhibitors and thrombus formation
@en
Clinical aspects of platelet inhibitors and thrombus formation
@nl
type
label
Clinical aspects of platelet inhibitors and thrombus formation
@ast
Clinical aspects of platelet inhibitors and thrombus formation
@en
Clinical aspects of platelet inhibitors and thrombus formation
@nl
prefLabel
Clinical aspects of platelet inhibitors and thrombus formation
@ast
Clinical aspects of platelet inhibitors and thrombus formation
@en
Clinical aspects of platelet inhibitors and thrombus formation
@nl
P3181
P1433
P1476
Clinical aspects of platelet inhibitors and thrombus formation
@en
P2093
Deepak L Bhatt
Telly A Meadows
P304
P3181
P356
10.1161/01.RES.0000264509.36234.51
P407
P577
2007-05-11T00:00:00Z